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The estrogen receptor a (ERa) controls cell prolifera-
tion and tumorigenesis by recruiting various cofac-
tors to estrogen response elements (EREs) to control
gene transcription. A deeper understanding of these
transcriptional mechanisms may uncover therapeu-
tic targets for ERa-dependent cancers. We show
that BRD4 regulates ERa-induced gene expression
by affecting elongation-associated phosphoryla-
tion of RNA polymerase II (RNAPII) and histone
H2Bmonoubiquitination. Consistently, BRD4 activity
is required for proliferation of ER+ breast and endo-
metrial cancer cells and uterine growth in mice.
Genome-wide studies revealed an enrichment of
BRD4 on transcriptional start sites of active genes
and a requirement of BRD4 for H2B monoubiquitina-
tion in the transcribed region of estrogen-responsive
genes. Importantly, we demonstrate that BRD4
occupancy on distal EREs enriched for H3K27ac is
required for recruitment and elongation of RNAPII
on EREs and the production of ERa-dependent
enhancer RNAs. These results uncover BRD4 as a
central regulator of ERa function and potential thera-
peutic target.INTRODUCTION
Estrogen receptor-positive (ER+) breast cancers represent a
significant challenge to modern health care. ERa-dependent
transcription in these cancers potentiates cell proliferation and460 Cell Reports 8, 460–469, July 24, 2014 ª2014 The Authorsmalignancy. Estrogen (E2) binding leads to conformational
changes within ERa that promote dimerization, binding to
estrogen response elements (EREs), and subsequent cofactor
recruitment (Deroo and Korach, 2006). Binding of ERa to EREs
is promoted by the pioneer factor, Forkhead protein FOXA1
(HNF3a) (Carroll et al., 2005; Hurtado et al., 2011). ERa also func-
tions along with Cohesin (Schmidt et al., 2010) to facilitate long-
range chromosomal interactions between EREs (Fullwood et al.,
2009).
The regulation of transcriptional elongation plays an essential
role in E2-dependent gene transcription. This is largely regulated
by the activity of the Positive Transcription Elongation Factor-b
(P-TEFb) complex (Peterlin and Price, 2006). P-TEFb promotes
elongation in part by relieving negative regulation by phosphor-
ylating negative elongation factor (NELF) and dichloro-1-b-D-
ribofuranosylbenzimidazole (DRB)-sensitivity inducing factor
(DSIF) complexes. Pausing of RNA polymerase II (RNAPII) by
NELF just downstream of the transcriptional start site (TSS)
is a critical determinant of ERa-dependent transcription (Aiyar
et al., 2004). P-TEFb also phosphorylates Ser2 (p-Ser2)
within the heptapeptide repeat of the RNAPII carboxy-terminal
domain (CTD). This in turn promotes elongation-associated his-
tone modifications including histone H2B monoubiquitination
(H2Bub1) (Karpiuk et al., 2012; Pirngruber et al., 2009), which
is required for E2-dependent transcription (Bedi et al., 2014;
Prenzel et al., 2011). Consistently, E2-dependent transcription
was shown to be regulated at a post-RNAPII recruitment step
involving increased RNAPII p-Ser2 by P-TEFb (Kininis et al.,
2009).
The Bromodomain-containing Protein 4 (BRD4) binds to acet-
ylated histones at both enhancers and promoters and recruits
P-TEFb to support lineage-specific gene transcription (Zippo
et al., 2009; Zhang et al., 2012b). Importantly, inhibition of
BRD4 by pan-bromodomain and extraterminal domain (BET)
Figure 1. BRD4 Perturbation Impairs E2-Induced Gene Expression, RNA Polymerase Ser2 Phosphorylation, and H2Bub1
(A) Heatmapmade with log2-fold changes frommRNA-seq of MCF7 cells. E2 denotes siCont and E2-treated samples relative to cells transfected with siCont and
Veh treated. siBRD4+E2 denotes siBRD4 and E2-treated samples relative to siCont with E2 induction. JQ1+E2 denotes siCont, JQ1, and E2-treated samples
relative to siCont with E2 induction. Only E2-upregulated genesR1.5-fold are shown. Adjusted p value is%0.05.
(B) GSEA of mRNA expression data from RNA-seq. The table shows the enrichment score for the topmost estrogen-related pathways in each condition. Nominal
p value is%0.05, FDR%25%.
(C andD)Western blot analyseswith specific antibodies onwholeMCF7 protein extracts after transfection with negative control () or siBRD4with 6 or 24 hr of E2
induction (C) or DMSO () or JQ1 and/or E2 induction for 24 hr (D). Relative quantified values of H2Bub1 normalized with H2B and ERawith HSC70 are indicated
under the respective blots.
See also Figures S1A–S1J.inhibitors such as JQ1 (Filippakopoulos et al., 2010), PFI-1 (Pic-
aud et al., 2013), and IBET revealed the involvement of BRD4 in
various cancers in animal models (Herrmann et al., 2012; Lock-
wood et al., 2012; Ott et al., 2012; Zhang et al., 2012a; Zuber
et al., 2011). Moreover, a BRD4-dependent gene expression
signature was reported to be a positive predictor of breast can-
cer survival (Crawford et al., 2008) and has been implicated as
an inherent susceptibility gene for metastasis in breast cancers
(Alsarraj et al., 2011).
Recent findings describe a role for enhancer RNA (eRNA) pro-
duction from ERa-bound enhancers during E2-regulated tran-
scription (Hah et al., 2013; Li et al., 2013). eRNAs are noncoding
RNAs that promote transcription by an unknown mechanism
(Kim et al., 2010). Interestingly, cyclin-dependent kinase 9
(CDK9) is required for E2-regulated eRNA synthesis (Hah et al.,
2013).
In this study, we investigated a role for BRD4 as a transcrip-
tional cofactor of ERa-induced transcription by regulating tran-scriptional elongation and revealed its recruitment both to
gene promoters as well as FOXA1-ERa-bound enhancers in
ER+ breast cancer cells. Moreover, we demonstrate that distal
EREs that produce eRNAs are enriched for BRD4 occupancy
and uncover a role for BRD4 in eRNA synthesis.
RESULTS
BRD4 Regulates E2-Induced Transcriptional Activity in
ER+ Cancers
To analyze the importance of BRD4 in ERa-dependent gene
regulation, we performed mRNA sequencing (mRNA-seq) ana-
lyses in ER+ breast cancer cells following E2 stimulation in cells
depleted for BRD4 or treated with the BRD4 inhibitor, JQ1 (Fig-
ure S1A). Heatmap analysis shows a nearly global decrease
of E2-stimulated gene expression following BRD4 depletion
and inhibition (Figures 1A and S1C), whereas the effects of
BRD4 perturbation in this time frame were less apparent forCell Reports 8, 460–469, July 24, 2014 ª2014 The Authors 461
Figure 2. Inhibition andKnockdownof BRD4Affect Proliferation and
Uterine Growth
(A) Cell proliferation assays in MCF7 cells upon E2 as well as basal conditions
under negative siCont, siBRD4, JQ1, and ICI182780 treatment.
(B–D) Three-week-old mice injected with Veh (Cont [control]) and JQ1 for
3 weeks were dissected, and uteri were analyzed for their size (B) and wet
weight (wt.) (C). ***p% 0.001. Data are represented as mean ± SD (n = 8). (D)
Single-gene expression analyses of E2-induced genes (Ran,Mad2l1, and Il1b)
after Veh (cont) or JQ1-injected mouse uteri. *p% 0.05; **p% 0.01. The data
are represented as median ± SD (n = 4). Rel. mRNA exp., relative mRNA
expression.
See also Figures S2A–S2C.E2-downregulated genes (Figure S1D). The inhibition of E2-
induced transcription by BRD4 perturbation was further verified
for representative E2-upregulated genes (Figure S1B). Strikingly,
in addition to the known targets of BRD4 such as cell prolifera-
tion-specific and tumor necrosis factor-nuclear factor kB target
genes (Mochizuki et al., 2008; Zou et al., 2014), gene set enrich-
ment analyses (GSEAs) identified multiple E2- and ERa-related
pathways as being significantly enriched following BRD4 knock-
down or inhibition under vehicle (Veh) as well as E2-treated con-
ditions (Figures 1B, S1E, and S1F). Similar effects were also seen
in the ER+ Ishikawa endometrial cancer cell line (Figure S1G),
whereas BRD4 depletion had little or no effect on transforming
growth factorb1 (TGF-b1)-inducedgeneexpression (FigureS1H).
Together, these findings indicate a specific and central role for
BRD4 in regulating E2-induced transcription in ER+ cancers.462 Cell Reports 8, 460–469, July 24, 2014 ª2014 The AuthorsBRD4 Regulates RNAPII Phosphorylation and H2Bub1
Given the importance of BRD4 in controlling RNAPII elongation
(Liu et al., 2013; Patel et al., 2013), and the established roles
for RNAPII p-Ser2 (Kininis et al., 2009) and H2Bub1 (Prenzel
et al., 2011) in E2-induced gene transcription, we examined
whether BRD4 depletion or inhibition affects RNAPII p-Ser2
or H2Bub1. Interestingly, both RNAPII p-Ser2 and H2Bub1 sub-
stantially increased upon E2 treatment, and depletion or inhibi-
tion of BRD4 decreased their levels under basal as well as
E2-induced conditions (Figures 1C, 1D, and S1J). Similar effects
were also observed in Ishikawa and H1299 cells upon BRD4
depletion (Figure S1I).
BRD4 Regulates ERa-Dependent Cell Proliferation and
Uterine Growth
In order to investigate the physiological function of BRD4 in con-
trolling ERa activity, we examined cell proliferation after knock-
down or inhibition of BRD4 in both MCF7 and Ishikawa cells.
Notably, consistent with gene expression results (Figures 1A,
1B, and S1B–S1F), BRD4 perturbation decreased cell prolifera-
tion in a manner similar to the pure anti estrogen ICI182780 both
in the presence and absence of E2 (Figures 2A, S2A, and S2B).
Decreased uterine weight is a hallmark of diminished estrogen
signaling in vivo. Consistent with in vitro experiments, JQ1-
injected mice demonstrated a substantial decrease in uterine
growth (Figure 2B) and uterine wet weight (Figure 2C), without
significant changes in total body weight (Figure S2C). Gene
expression analyses confirmed decreased expression of E2-
dependent genes in uteri from JQ1-injected mice (Figure 2D),
confirming a central role for BRD4 in controlling E2-induced pro-
liferation and growth both in vitro and in vivo.
BRD4 Occupancy Is Associated with an Active
Epigenetic Context and Transcription
Togainmechanistic insight into the functionofBRD4andH2Bub1
inERa-regulated transcription,weperformedgenome-widechro-
matin immunoprecipitation (ChIP) and sequencing (ChIP-seq)
analyses. Consistent with its role in E2-induced gene transcrip-
tion, genome-wide profiling and single-gene analyses revealed
increased BRD4 occupancy slightly downstream of the TSS
and continuing into the transcribed region of E2-induced genes
(Figures 3A, 3B, and S3A–S3G). This occupancy is decreased
upon JQ1 treatment (Figure S3B). Conversely, E2 reduced
BRD4 recruitment on E2-repressed genes (Figures S3D and
S3F). Consistent with a previous study by Minsky et al. (2008),
H2Bub1 preferentially occupied gene bodies (Figures 3C, 3D,
and S3H–S3L). Notably, E2 treatment increased H2Bub1 levels
on E2-stimulated genes significantly, and this effect was
reduced by JQ1 treatment (Figures 3C, S3I, andS3K–S3M). Inter-
estingly, the effect of JQ1 on H2Bub1 occupancy was most
pronounced on genes exhibiting de novo RNAPII recruitment,
such asGREB1 and TFF1, but less onRNAPII-recruited and -pre-
loaded and -constitutively bound genes like XBP1 (Figures S3K
and S3N).
Correlation and aggregate plots confirmed an association
of BRD4 and active transcription on E2-induced TSSs (Figures
3E, 3F, and S3O–S3R). Moreover, BRD4 occupancy positively
correlated with histone marks H3K27ac and H3K4me3, which
Figure 3. BRD4 Occupies Promoters and Correlates with Active Transcription
(A) Genomic binding profiles of BRD4 on E2-induced genes (GREB1 and TFF1) and a housekeeping gene (ACTB). Red indicates E2-treated and green indicates
Veh-treated conditions.
(B) Aggregate plots showing genomic binding profiles of BRD4 on E2-upregulated gene-specific TSS upon Veh and E2-treated conditions. x axis shows the
distance from the TSS of E2-upregulated genes in kilobase pairs. y axis shows the average BRD4 signal of the reads normalized per hundred million base pairs.
TSS is marked with a black dotted line.
(C) Aggregate plots showing genomic profiles of H2Bub1 on E2-upregulated genes upon Veh, JQ1, as well as Veh (JQ1 Veh), E2, and JQ1 as well as E2 (JQ1 E2)-
treated conditions. Weighted averages for each E2-upregulated gene, 1.5–2.5 kb downstream of each TSS, were used to calculate the p values using ANOVA
with multiple-regression model. ***p% 0.001.
(D) Genomic profiles of H2Bub1 on GREB1, TFF1, and ACTB. Red indicates E2-treated and green indicates JQ1 as well as E2 (JQ1 E2)-treated conditions.
(E) Correlation plot on E2-regulated gene-specific TSS +3 kb showing the association of BRD4, H3K27ac, H3K4me3, nascent RNA transcription (GRO-seq),
RNAPII, H2Bub1, and DNase I-hypersensitivity sites (DNase-seq) and H3K27me3.
(F) Aggregate plot analyses of BRD4, H3K27ac, RNAPII, and H2Bub1 on GRO-seq-based groups (high, medium, low, and null), at specific TSSs on E2-regulated
genes. ‘‘High’’ group corresponds to E2-upregulated TSS having aweighted average of GRO-seq signal fromE2-treatedMCF7 cells >0.3, ‘‘medium’’R0.15 <0.3,
‘‘low’’ >0 <0.15, and ‘‘null’’ with no value of average. A class of H3K27me3-positive summits was examined as a negative control of active transcription.
See also Figures S3A–S3R.are hallmarks of active transcription, as well as RNAPII,
H2Bub1, and DHSs (DNase I-hypersensitivity sites), but not
with H3K27me3 (Figures 3E and S3O). Similarly, H2Bub1 also
correlated with transcription, H3K4me3, BRD4, H3K27ac,
and RNAPII (Figures 3E and S3O). Grouping of TSSs according
to the level of nascent RNA expressed (high, medium, low, and
null) and aggregate plot and heatmap analyses revealed a
clear association of BRD4, H3K27ac, H3K4me3, RNAPII, and
H2Bub1 occupancy as well as DHSs and gene transcription
(Figures 3F and S3P–S3R).BRD4 Functions Downstream of ERa, H3K27ac, and
Cohesin
Because BRD4 inhibition prevents E2-dependent gene induction
without appreciably affecting ERa protein levels (Figures 1D and
S4A), we also examined the effects of JQ1 treatment on the
recruitment of ERa and the Cohesin subunit RAD21. Single-
gene analyses of ERa binding suggested that ERa binding is
not affected at specific EREs after BRD4 inhibition (Figures 4A
and S4B). Consistent with a recent report describing an effect
of BRD4 inhibition on androgen receptor (AR) recruitmentCell Reports 8, 460–469, July 24, 2014 ª2014 The Authors 463
(legend on next page)
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(Asangani et al., 2014), genome-wide analyses confirmed that
JQ1 treatment decreases ERa binding at most EREs (Figures
4B, S4D, and S4E). However, these effects are only partial,
and substantial levels of ERa are still bound to EREs after JQ1
treatment (Figure S4F). Consistent with the recent studies that
BRD4 does not promote chromosomal looping between en-
hancers and promoters (Liu et al., 2013), RAD21 binding to three
different EREs known to serve as hubs for ERa-dependent loop-
ing (Fullwood et al., 2009) was unaffected by JQ1 treatment
(Figure S4C). Interestingly, whereas BRD4 binding correlated
with H3K27ac (Figure 3E) (Zhang et al., 2012b), BRD4 inhibi-
tion did not influence the E2-induced H3K27ac on individual
E2-regulated enhancers and promoters (Figures 4C and S4H).
These results suggest that BRD4 is recruited to E2-regulated
genes subsequent to ERa binding, histone acetylation, and
Cohesin recruitment.
BRD4 Occupies Enhancers and Regulates eRNA
Synthesis by Affecting RNAPII Recruitment and
Elongation
BRD4 was recently shown to occupy and regulate enhancer
function (Liu et al., 2013; Zhang et al., 2012b). Thus, we exam-
ined BRD4 occupancy at distal EREs and observed that BRD4
is recruited to distal EREs in an E2-dependentmanner and corre-
lated with H3K27ac, ERa, FOXA1, RNAPII, and DHS (Figures 4D,
4E, 4H, S4G, and S4I–S4L). Surprisingly, nascent RNA transcrip-
tion on enhancers correlated with BRD4 occupancy to a greater
extent than the other investigated profiles (Figures 4E–4H).
RNAPII occupancy is also well associated with BRD4 on en-
hancers (Figure 4E). Interestingly, high eRNA-producing EREs
exhibited high E2-induced RNAPII recruitment that extended to
more than 5 kb upstream and downstream of the ERE summits,
suggesting a tight association between RNAPII recruitment andFigure 4. BRD4 Binds to ER+ Enhancers after ERa Recruitment and H3
(A) ChIP-quantitative PCR (ChIP-qPCR) analyses of ERa occupancy onGREB1 ER
represented as mean ± SD (n = 3). Dotted line indicates background.
(B) Aggregate plot showing genomic binding profiles of ERa on distal EREs upon
distance from the center of ERE in kilobase pairs. y axis shows the average ERa sig
for each ERE ±100 bp were used to calculate the p values using ANOVA with
mentioned in the plot.
(C) ChIP-qPCR analyses of H3K27ac after DMSO or JQ1 treatment with Veh or E
represented as mean ± SD (n = 3). **p% 0.01; n.s., not significant.
(D) Aggregate plot showing genomic binding profiles of BRD4 on distal EREs up
(E) Correlation plot on distal EREs ±1.5 kb showing the association of BRD4, H3K2
and H3K27me3.
(F) Aggregate plot analyses of BRD4, H3K27ac, ERa, FOXA1, and RNAPII occup
distal EREs having a weighted average >0.45, ‘‘medium’’ >0.25 <0.45, ‘‘low’’ >0
(G) Heatmap profiles of BRD4, H3K27ac, ERa, FOXA1, nascent RNA transcription
null GRO-seq signals. Center of each heatmap denotes center of distal EREs.
(H) Binding profiles of BRD4, H3K27ac, ERa, GRO-seq, and RNAPII onGREB1 pro
and green indicates Veh-treated conditions. RNAPII with blue peaks indicates E
(I) Aggregate plot showing genomic binding profiles of RNAPII on distal EREs
conditions.
(J and K) ChIP-qPCR analyses of RNAPII (J) and RNAPII-PSer2 (K) occupancy on
Data are represented as mean ± SD (n = 3). Dotted line indicates background.
(L) eRNA-qPCR results showing E2-induced eRNA (eGREB1 and eXBP1) upon ne
levels are shown as ‘‘Rel. RNA levels.’’ Data are represented as mean ± SD (n =
(M) Model depicting the role of BRD4 on E2-induced transcription. ER, ERa; HA
H2Bub1.
See also Figures S4A–S4N.elongation at eRNA-producing enhancers (Figures 4I and S4N).
ChIP analyses confirmed that E2-induced RNAPII recruitment
and elongation at the GREB1 ERE are decreased by JQ1 treat-
ment (Figures 4J, 4K, and S4O). Altogether, these studies sug-
gest that in addition to its role in transcriptional elongation,
BRD4 affects both recruitment and elongation of RNAPII on
ERa-dependent enhancers.
Importantly, BRD4 depletion or inhibition significantly
decreased eRNA synthesis from E2-regulated enhancers (Fig-
ure4L). This suggests that in addition to its reportedcis-regulatory
function, BRD4 may stimulate E2-induced mRNA transcription
by promoting eRNA production at distal EREs.
DISCUSSION
The hierarchical epigenetic regulation of transcriptional
activation involves an intricate network of interactions among
various transcription factors, histone-modifying enzymes, epige-
netic readers, and the transcriptional machinery. In this study,
we investigated the function of the epigenetic reader BRD4 in
controlling E2-regulated gene transcription. Our findings support
a model in which ERa recruits histone acetyltransferases to a
subset of EREs enriched for FOXA1 to facilitate histone acetyla-
tion and subsequent recruitment of BRD4 and RNAPII in order to
promote eRNA synthesis (Figure 4M).
To date, most studies have focused largely on the role of
BRD4 as a promoter proximal regulator of mRNA synthesis by
increasing P-TEFb recruitment. Consistent with a direct function
of BRD4 on target gene transcription, we show that BRD4 pro-
motes elongation-associated phosphorylation of RNAPII and
monoubiquitination of histone H2B. These results are consistent
with an established essential role for H2Bub1 in E2-stimulated
transcription (Prenzel et al., 2011) and the dependence ofK27ac and Regulates eRNA Synthesis
E after DMSOor JQ1 treatment with Veh or E2 induction. ***p% 0.001. Data are
E2-treated and JQ1 as well as E2 (JQ1 E2)-treated conditions. x axis shows the
nal of the reads normalized per hundredmillion base pairs. Weighted averages
repeated measures with ANOVA with multiple-regression model. p value is
2 induction on GREB1 ERE overlapping region and GREB1 TSS. The data are
on Veh and E2-treated conditions.
7ac, ERa, FOXA1, nascent RNA transcription (GRO-seq), RNAPII, DNase-seq,
ancy on GRO-seq-based classified distal EREs. ‘‘High’’ group corresponds to
% 0.25, and ‘‘null’’ with no value of average.
(GRO-seq), and RNAPII occupancy on ±5 kb of distal EREs aligned from high to
ximal and distal EREs and promoter. BRD4with red peaks indicates E2-treated
2-treated and light green indicates Veh-treated conditions.
that produce high eRNA (GRO-seq group ‘‘high’’) upon Veh and E2-treated
GREB1 ERE after DMSO or JQ1 treatment with Veh or E2 induction. *p% 0.05.
gative siCont, siBRD4, or JQ1 treatment with Veh or E2 induction. Relative RNA
3).
T, histone acetyltransferase; ac, histone acetylation; S2P, RNAPII p-Ser2; Ub,
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H2Bub1 upon CDK9 (Pirngruber et al., 2009). In addition to a cis-
regulatory function of BRD4, our results uncover a role for BRD4
on enhancers. This is consistent with a previous finding that
CDK9 is recruited by BRD4 to distal intergenic enhancer
regions marked by H3K27ac (Love´n et al., 2013). Notably, we
show that BRD4 co-occupies eRNA-producing enhancers with
ERa, FOXA1, and H3K27ac, regulates RNAPII recruitment on
ERa-bound enhancers, and is required for the production of
eRNA transcripts. These findings support a role for BRD4 in
hormone-dependent cancers (Asangani et al., 2014) and sug-
gest a model in which eRNA synthesis requires a coordinated
epigenetic hierarchy that culminates in the recruitment of
BRD4 and RNAPII and subsequent transcription from a select
subset of distal EREs.
The importance of BRD4 in E2-regulated transcription is
consistent with previously identified interactions between
BRD4 and ERa (Wu et al., 2013) as well as ERa and CDK9 (Sharp
et al., 2006) or cyclin T1 (Wittmann et al., 2005). Furthermore, the
7SK component HEXIM1, which suppresses P-TEFb activity,
negatively regulates ERa transcriptional activity (Wittmann
et al., 2005), and its overexpression induces tamoxifen resis-
tance (Ketchart et al., 2011). Importantly, recent data showed
that CDK9 activity is required for the production of eRNAs at
distal EREs (Hah et al., 2013) and the role of eRNA and MED1
in regulating AR-dependent transcription and looping (Hsieh
et al., 2014). Thus, consistent with our model, P-TEFb and
BRD4 likely promote ERa-mediated transcriptional activation
at least in part by promoting eRNA transcription.
ERa functions together with Cohesin to nucleate chromo-
somal looping that promotes E2-regulated transcription (Full-
wood et al., 2009; Schmidt et al., 2010). Our previous study
showed that proteasomal inhibition specifically decreases
ERa-regulated transcription by decreasing H2Bub1 and tran-
scriptional elongation without affecting long-range chromo-
somal interactions (Prenzel et al., 2011). Consistently, CDK9
inhibition decreased ERa-dependent gene expression without
affecting ERa occupancy, coactivator recruitment, or chromo-
somal looping (Hah et al., 2013). Similarly, our data show that
BRD4 inhibition had little or no effect on ERa recruitment,
E2-stimulated H3K27 acetylation, or Cohesin recruitment, indi-
cating that BRD4 functions along with CDK9 downstream of
early enhancer activation events but precedes RNAPII recruit-
ment and elongation.
Numerous recent studieshave shownasubstantial therapeutic
potential for BRD4 inhibition in variousmalignant diseases (Asan-
gani et al., 2014; Filippakopoulos et al., 2010; Herrmann et al.,
2012; Lockwood et al., 2012; Ott et al., 2012; Zhang et al.,
2012a; Zuber et al., 2011), leading to the testing of several BET
domain inhibitors in a clinical setting for certain types of tumors
(Filippakopoulos andKnapp, 2014).However, theutility ofBET in-
hibitors in ERa+ breast cancer has not been investigated. Here,
we describe a function of BRD4 in specifically controlling E2-
dependent gene transcription in ERa+ normal andmalignant cells
in vitro and in vivo. We provide mechanistic insight to support a
previously unknown mechanism by which BRD4 controls distal
enhancer activity and target gene expression by promoting
eRNA synthesis. We hypothesize that this BRD4-dependent
mechanism likely controls other enhancer-driven transcriptional466 Cell Reports 8, 460–469, July 24, 2014 ª2014 The Authorsprograms directing processes such as lineage specification
during cell differentiation and development. Moreover, these
findings may potentially serve to provide a mechanistic-based
approach to the treatment of ERa+ breast cancer.
EXPERIMENTAL PROCEDURES
Cell Culture, Transfections, Inhibitors, and siRNAs
MCF7 cells were provided by K. Pantel (University Medical Center, Hamburg-
Eppendorf), Ishikawa from T. Spelsberg (Mayo Clinic, Rochester), and H1299
from M. Dobbelstein (University Medical Center, Go¨ttingen). They were grown
in phenol red-free high-glucose Dulbecco’s modified Eagle’s media (DMEMs;
Invitrogen) supplemented with 10% bovine growth serum (Thermo Scientific),
1% sodium pyruvate, and 1% penicillin/streptomycin (Sigma-Aldrich). For-
ward and reverse transfections were performed using DharmaFECT 1 (Thermo
Scientific) for small interfering RNAs (siRNAs) according to the manufacturer’s
instructions. Nontargeting (negative control) and BRD4 siRNAs (siBRD4s)
were obtained from Dharmacon (Thermo Scientific). BRD4 SmartPool siRNA
(Dharmacon) contained the sequences 50-AGCUGAACCUCCCUGAUUA-30,
50-UGAGAAAUCUGCCAGUAAU-30, 50-UAAAUGAGCUACCCACAGA-30, and
50-GAACCUCCCUGAUUACUAU-30. JQ1 (150 nM) was used to pretreat the
cells 30 min before E2 induction. 17 b-estradiol and ethinyl estradiol (Sigma-
Aldrich) were used at the concentration of 10 nM. DMSO or ethanol was
used as Veh. ICI182780 (Fulvestrant) was used at the concentration of 1 mM.
TGF-b1 (2 ng/ml) treatment was done on H1299 cells for 90 min.
E2-induction experiments were carried out by changing the media to
DMEM supplemented with 5% charcoal-dextran-treated fetal bovine serum
(CSS; Sigma-Aldrich), 1% sodium pyruvate, and 1% penicillin/streptomycin
after 24 hr of cell growth. After 48 hr of hormone deprivation, they were treated
with 17 b-estradiol for 2, 6, or 24 hr. Ethinyl estradiol was used for proliferation
assays in Ishikawa cells. TGF-b1 treatment in H1299 cells was given after
growing the cells in serum-free media for 48 hr.
MCF-7 cells were harvested for RNA upon Veh or E2 treatment, and negative
control siRNA (siCont), siBRD4, or JQ1 transfection. JQ1-treated cells were
also transfected with negative siCont. Ishikawa and H1299 cells were har-
vested for RNA under Veh or E2 treatment, or TGF-b1 treatment and negative
siCont or siBRD4.
RNA-Seq
RNA integrity was checked using Bioanalyzer 2100 (Agilent Technologies).
A total of 500 ng of total RNA was used for preparing libraries using TruSeq
RNA Sample Preparation Kit (Illumina), and the size range was checked to
be 280 bp using Bioanalyzer. These samples were amplified and sequenced
by using cBot and HiSeq 2000 from Illumina, respectively, for 51 bp single-
ended tagswith single indexing. Images from the sequencing results were pro-
cessed using BaseCaller to bcl files function in Illumina software. These were
demultiplexed to fastq files using CASAVA 1.8.2 and mapped to the human
reference transcriptome (UCSC HG19) using Bowtie 2 (version 2.1.0) (Lang-
mead and Salzberg, 2012). Read counts for each sample and each gene
were aggregated using a custom Ruby script. DESeq (version 1.14.0) was
used for measuring differential expression (Anders and Huber, 2010).
Gene Set Enrichment Analysis
Pathway enrichment scores were calculated by GSEA (Subramanian et al.,
2005). The gene expression data from RNA sequencing (RNA-seq) analyses
are sorted by correlation with log2-fold changes between different
conditions. This sorted expression data set was compared with C2-curated
gene sets that include published gene sets from pathways of chemical
and genetic perturbations, canonical pathways, BIOCARTA, Reactome,
and KEGG. WILLIAMS_ESR1_TARGETS_UP (Williams et al., 2008),
FRASOR_RESPONSE_TO_ESTRADIOL_UP (Frasor et al., 2004),
MASSERWEH_RESPONSE_TO_ESTRADIOL (Massarweh et al., 2008),
BHAT_ESR1_TARGETS_NOT_VIA_AKT1_UP (Bhat-Nakshatri et al., 2008),
DUTERTRE_ESTRADIOL_RESPONSE_6HR_UP (Dutertre et al., 2010),
PID_HNF3A_PATHWAY (Schaefer et al., 2009), STEIN_ESR1_TARGETS
(Stein et al., 2008), MASSERWEH_TAMOXIFEN_RESISTANCE_DN
(Massarweh et al., 2008), and CREIGHTON_ENDOCRINE_THERAPY_
RESISTANCE_4 (Creighton et al., 2008) are shown as E2-related topmost
enriched pathways under BRD4 perturbation.
ChIP
ChIP and subsequent real-time PCR analyses with specific primers (Table S3)
were performed as before (Prenzel et al., 2011; Bedi et al., 2014) for BRD4,
ERa, RAD21, H3K27ac, and H2Bub1. ChIP-seq was performed for BRD4,
ERa, and H2Bub1. BRD4 ChIP was performed by crosslinking the chro-
matin for 20 min in 1% formaldehyde. Other antibodies and their dilutions
were used as described before (Table S1) (Prenzel et al., 2011; Bedi et al.,
2014).
ChIP-Seq and Bioinformatic Analyses
Prior to library preparation, immunoprecipitated DNA was sonicated an addi-
tional time to ensure fragment sizes less than 200 bp. Libraries were prepared
using the NEBNext Ultra DNA library preparation kit according to the manu-
facturer’s instructions. Size range was verified to be 280–300 bp using Bio-
analyzer 2100. A total of 50 cycles were used for amplification in cBot, and
101 bp single-ended tags for BRD4 and 51 bp single-ended tags for other
ChIP samples were sequenced with single indexing using Illumina HiSeq
2500. Raw data for FOXA1, H3K4me3, H3K27me3 (Joseph et al., 2010),
H3K27ac (Theodorou et al., 2013), RNAPII (Welboren et al., 2009), DNase
sequencing (DNase-seq) (Thurman et al., 2012), and global run-on (GRO)
sequencing (GRO-seq) (Hah et al., 2013) were downloaded from the Euro-
pean Nucleotide Archive, and their accession numbers are listed in Table
S4. The reads were mapped to the human reference genome (UCSC HG19)
using Bowtie (version 1.0.0) (Langmead et al., 2009). Peak calling was done
by Model-based Analysis of ChIP-Seq (version 1.4.2) (Zhang et al., 2008).
Coverage was determined by normalizing the total number of mapped reads
per hundred million. For plotting correlation, aggregation, ChIP enrichment
signals over specific genomic features, and heatmaps, Cistrome (Liu et al.,
2011) based on the Galaxy framework was used. Data were visualized in
Integrative Genomics Viewer (version 2.3.14) (Thorvaldsdo´ttir et al., 2013).
Common TSS and gene body coordinates were obtained from UCSC Table
Browser (Karolchik et al., 2004). Distal EREs were defined as ERa binding
sites not within gene bodies or regions 5 kb upstream or downstream thereof.
Regions covering the TSS and 3 kb downstream of it were used for TSS-ori-
ented correlation plots and 1.5 kb up- and downstream to distal EREs for
distal ERE-oriented correlation plots. Average signals of GRO-seq data with
E2 treatment were calculated using assign weighted average function in Cis-
trome surrounding TSS (plus 3 kb) or ERE (±1.5 kb). These values were used
to group the TSS or ERE coordinates as high, medium, low, and null. For
distal EREs, the ‘‘high’’ group corresponds to distal EREs having a weighted
average greater than 0.45, ‘‘medium’’ has >0.25 <0.45, ‘‘low’’ has >0%0.25,
and ‘‘null’’ has a zero (0) average. For TSSs, the ‘‘high’’ group corresponds
to distal EREs having a weighted average greater than 0.3, ‘‘medium’’
hasR0.15 <0.3, ‘‘low’’ has >0 <0.15, ‘‘null’’ has a zero (0) average. The range
for these groups was chosen according to the similar number of TSSs or
EREs in each group and adequate GRO-seq enrichment signal defined for
each group. H3K27me3-positive coordinates were obtained using the sum-
mits of H3K27me3 ChIP-seq signal (Joseph et al., 2010). For measuring
statistical significance of aggregate plots, weighted averages for each E2-up-
regulated gene, 1.5–2.5 kb downstream of each TSS or distal ERE ±100 bp,
were used to compute a multiple-linear regression model. Within the multiple-
linear regression model, the weighted average within a 1 kb window was
used as a dependent variable, given the independent variables of condition
and gene. The condition variable was tested for significant impact using an
ANOVA. Groups of E2-upregulated genes based on RNAPII occupancy
(RNAPII recruited de novo, RNAPII preloaded and recruited, and RNAPII
constitutively bound) were kindly provided by W. Lee Kraus. E2 up- (R1.5-
fold), down- (%0.8-fold), and nonregulated genes were retrieved from
RNA-seq data.
In Vivo Experiments in JQ1-Injected Mice
Three-week-old C57BL/6 female mice were injected intraperitoneally with JQ1
(50 mg/kg) or Veh (5% DMSO in 5% dextrose) for 3 weeks (n = 8 for eachgroup). Mice were sacrificed via CO2 inhalation, and uteri were collected to
examine differences in their size and weight. Difference in the uterine weight
between control (DMSO) and JQ1-injected mice was calculated by normal-
izing the uterine wet weight (in milligrams) with respect to body weight
(in grams). Uteri (n = 4 for each group) were homogenized using beads by
FastPrep FP120 homogenizer (Thermo Scientific), and RNAwas isolated using
TRIzol (QIAGEN) according to manufacturer’s instructions. Normalization was
done using starting quantity values of glyceraldehyde 3-phosphate dehydro-
genase. Relative mRNA expression analyses were done as mentioned before
(but not normalized for control conditions) using gene-specific primers
for the E2-dependent and cell-cycle-related genes Ran and Mad2l1 (Suzuki
et al., 2007) and the reproduction-related gene Il1b (Weihua et al., 2000).
Primers are listed in Table S2. Statistical significance was analyzed using
Student’s t test. All animal studies were performed in compliance with the
requirements of the German Animal Welfare Act.
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